Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with Royalty ...
Procter & Gamble is trading near the top of the Dow Wednesday after the consumer staples giant beat expectations for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback